Myelofibrosis

Common Name(s)

Myelofibrosis

Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue.  Scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. Although myelofibrosis can occur at any age, it typically develops after the age of 50.  In most cases, myelofibrosis gets progressively worse. Treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelofibrosis" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelofibrosis" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelofibrosis" returned 345 free, full-text research articles on human participants. First 3 results:

JAK inhibitor in CALR-mutant myelofibrosis.
 

Author(s): Mario Cazzola, Robert Kralovics

Journal: N. Engl. J. Med.. 2014 Mar;370(12):1169.

 

Last Updated: 20 Mar 2014

Go To URL
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
 

Author(s): Christen L Andersen, Nana B Mortensen, Tobias W Klausen, Hanne Vestergaard, Ole W Bjerrum, Hans C Hasselbalch

Journal: Haematologica. 2014 Jan;99(1):e5-7.

 

Last Updated: 15 Jan 2014

Go To URL
Mutational spectrum defines primary and secondary myelofibrosis.
 

Author(s): Ken I Mills, Mary Frances McMullin

Journal: Haematologica. 2014 Jan;99(1):2-3.

 

Last Updated: 15 Jan 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelofibrosis" returned 37 free, full-text review articles on human participants. First 3 results:

Beyond JAK inhibitor therapy in myelofibrosis.
 

Author(s): Olatoyosi Odenike

Journal: Hematology Am Soc Hematol Educ Program. 2013 ;2013():545-52.

 

Myelofibrosis (MF), including primary MF, postpolycythemia vera MF, and postessential thrombocythemia MF, is a clonal stem cell disorder characterized by BM fibrosis, extramedullary hematopoiesis, and a variable propensity to transform into acute leukemia. Allogeneic stem cell transplantation ...

Last Updated: 9 Dec 2013

Go To URL
Ruxolitinib for myelofibrosis--an update of its clinical effects.
 

Author(s): Hagop M Kantarjian, Richard T Silver, Rami S Komrokji, Ruben A Mesa, Roland Tacke, Claire N Harrison

Journal: Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45.

 

Myelofibrosis (MF), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by progressive bone marrow fibrosis and ineffective hematopoiesis. Clinical hallmarks include splenomegaly, anemia, and debilitating symptoms. In 2 randomized phase III studies, the ...

Last Updated: 18 Nov 2013

Go To URL
Advances in myelofibrosis: a clinical case approach.
 

Author(s): John O Mascarenhas, Attilio Orazi, Kapil N Bhalla, Richard E Champlin, Claire Harrison, Ronald Hoffman

Journal: Haematologica. 2013 Oct;98(10):1499-509.

 

Primary myelofibrosis is a member of the myeloproliferative neoplasms, a diverse group of bone marrow malignancies. Symptoms of myelofibrosis, particularly those associated with splenomegaly (abdominal distention and pain, early satiety, dyspnea, and diarrhea) and constitutional symptoms, ...

Last Updated: 4 Oct 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
 

Status: Available

Condition Summary: Myelofibrosis (PMF); Post Polycythemia Myelofibrosis (PPV MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF); Myelofibrosis; Post Polycythemia Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

 

Last Updated: 6 Jul 2014

Go to URL
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
 

Status: Recruiting

Condition Summary: Idiopathic Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia-Vera Myelofibrosis

 

Last Updated: 3 Apr 2014

Go to URL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
 

Status: Recruiting

Condition Summary: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

 

Last Updated: 11 Aug 2014

Go to URL